Inno-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 10, 2023 at 12:00 am IST
Share
Inno-Gene S.A. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was PLN 0.16 million compared to PLN 1.18 million a year ago. Revenue was PLN 0.16 million compared to PLN 1.18 million a year ago. Net loss was PLN 0.561 million compared to PLN 1.55 million a year ago.
For the nine months, sales was PLN 0.981 million compared to PLN 15.77 million a year ago. Revenue was PLN 0.981 million compared to PLN 15.77 million a year ago. Net loss was PLN 1.31 million compared to net income of PLN 0.665 million a year ago.
Inno-Gene SA is a Poland-based holding company engaged in management of a portfolio of companies active in life-science sector through the technology, research and development. Inno-Gene SA's portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
INNO-GENE S.A. 